AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03637361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 5 mg, 20 mg, 60 mg, 100 mg, 150 mg or 200 mg REL-1017, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL
Study NCT03637361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02830854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Molecular Hydrogen
Study NCT02047422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: furosemide (doubling previous furosemide dose)
Study NCT02047422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metolazone
Description: metolazone (add 2.5mg qod)
Study NCT02047422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemid/spironolactone
Description: spironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user)
Study NCT02047422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metolazone/spironolactone
Description: no spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user)
Study NCT00820443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceramic on metal prosthesis
Description: Ceramic femoral head with a metal acetabular component
Study NCT01303770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management cognitive rehabilitation group intervention
Description: 8-week cognitive rehabilitation program facilitated by an occupational therapist. Program goals include increased knowledge of cognitive impairments in multiple sclerosis, increased self-efficacy to manage cognitive changes and increased use of cognitive compensatory strategies.
Study NCT01303770 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: 8-week group program that is not specifically directed to management of cognitive impairments.
Study NCT05162716 — intervention group
Intervention type: DEVICE
Intervention: Single-chamber pacemaker implantation with left bundle branch area pacing
Description: A prepectoral single-chamber pacemaker is implanted with a 3830 (Medtronic) IS-1 pacing lead screwed via the right ventricle in the deep interventricular septum in order to capture the left Purkinje system on the left ventricular endocardial side.
Study NCT06396975 — intervention group
Intervention type: PROCEDURE
Intervention: robotic surgery
Description: robotic surgery
Study NCT04339283 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized Hibiscus sabdariffa tea
Description: Daily consumption of Standardized Hibiscus sabdariffa tea
Study NCT02664714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFMT
Description: Participating volunteers of all groups will receive guidance about the anatomy and function of the pelvic floor muscles (PFM) and how to perform a properly contraction: as strong as possible and eliminating at the most the contraction of the gluteus, abdominals and adductors. For all groups it will be used the same protocol which was developed for this study, with progression parameters of the PFMT based on the recommendations for the strength training of the American College of Sports Medicine (VICKI, 2001).
Study NCT02664714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFMT
Description: Participating volunteers of all groups will receive guidance about the anatomy and function of the pelvic floor muscles (PFM) and how to perform a properly contraction: as strong as possible and eliminating at the most the contraction of the gluteus, abdominals and adductors. For all groups it will be used the same protocol which was developed for this study, with progression parameters of the PFMT based on the recommendations for the strength training of the American College of Sports Medicine (VICKI, 2001).
Study NCT03784053 — intervention group
Intervention type: OTHER
Intervention: Immersive virtual reality
Description: At the start of every session, the participants' top five occupational problems will be reviewed, and a list of apps corresponding to the desired occupational problem will be offered through the immersive virtual reality device (Oculus Go). There will be eight 30-minute virtual reality sessions.
Study NCT00463697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444H (100mcg)
Description: H salt
Study NCT00463697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00463697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M (25, 100 & 400 mcg)
Description: M salt
Study NCT00095797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R(+)XK469
Description: Given IV
Study NCT00095797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00095797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT02810379 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: written informed consent
Study NCT02810379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video+written informed consent
Study NCT03589040 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Etonogestrel 68Mg Implant
Description: Etonogestrel single-rod subdermal implant (68mg/rod) will be administered to all study participants
Study NCT03589040 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: rilpivirine
Description: Oral rilpvirine 25mg
Study NCT03589040 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: darunavir
Description: Oral darunavir+ritonavir 600/100mg
Study NCT01392625 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous hMSCs
Description: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
Study NCT01392625 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic hMSCs
Description: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
Study NCT02875652 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: 3 vials of 7,5 ml of peripherical blood will be collected at each blood sample.
Study NCT02397187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LOOP
Description: The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes.
Study NCT02397187 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LOOP
Description: The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes.
Study NCT01532921 — intervention group
Intervention type: PROCEDURE
Intervention: Tricuspid valve repair
Study NCT01532921 — intervention group
Intervention type: PROCEDURE
Intervention: Left-sided heart surgery
Description: Tricuspid valve repair was with the study device was only warranted if concomitant left-sided heart surgery was planned
Study NCT01532921 — intervention group
Intervention type: DEVICE
Intervention: Contour 3D Tricuspid Annuloplasty Ring
Description: Contour 3D Tricuspid Annuloplasty procedure was used during the tricuspid valve repair
Study NCT01055938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex Sodium
Description: Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
Study NCT01055938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Description: Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
Study NCT01761799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P3 Vaccine Promotion Package.
Description: P3 stands for Practice, Provider, and Patient level vaccine promotion package. The 5 obstetric practices randomized to the intervention arm will receive this comprehensive influenza and Tdap vaccine promotion package at the beginning of the study. Physicians and staff will be familiarized with each component, and practices will be instructed to implement each component to the best of their ability. The components include: posters, educational brochures, lapel buttons, provider-to-patient talking points, lists of nearby locations offering flu and/or Tdap vaccines (if not offered by the practice), identification of a vaccine champion within the practice, provider and staff training on vaccination during pregnancy, and use of an interactive, tablet-based educational tutorial for patients.
Study NCT02634320 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole Lauroxil
Description: Monthly IM injection
Study NCT06123845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: static CPAP 8 cmH2O
Description: Set static CPAP or PEEP pressure level at 8 cmH2O
Study NCT06123845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: static CPAP 5 cmH2O
Description: Set static CPAP or PEEP pressure level at 5 cmH2O
Study NCT02132130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGF166
Description: CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion
Study NCT01772108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip
Description: The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
Study NCT04432896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary protocol
Description: Dietary protocol to manage symptoms related to Systemic Nickel Allergy Syndrome.
Study NCT04432896 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary protocol
Description: Dietary protocol to manage symptoms related to Systemic Nickel Allergy Syndrome.
Study NCT05745584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron (beta3-adrenoceptor agonist), Anticholinergics
Description: Administration of Mirabegron (beta3-adrenoceptor agonist) for 8 weeks, and followed by subsequent administration of anticholinergics for 8 weeks
Study NCT01525368 — intervention group
Intervention type: BEHAVIORAL
Intervention: cognitive intervention
Description: Complex modular cognitive intervention focussing on memory aspects (e.g. internal memory strategies, external memory aids), other cognitive functions (e.g. attention) as well as social interactions.
Study NCT02690688 — intervention group
Intervention type: DEVICE
Intervention: determination of dynamic preload variables
Study NCT03420508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Ensartinib will be given at a dose of 225mg daily in the form of 100mg and 25mg capsules. Patients will receive treatment continuously in 28 day cycles. Patients will then have the same tumor specimen biopsied again at day 15. Treatment will continue until disease progression, unacceptable toxicity, or patient choice to discontinue therapy.
Study NCT03623802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Movement Therapy
Description: Loads and intensity of exercises will be increased according to participants' abilities. Modifications of exercises are made through different body positions or increasing the load. When a participant will be able to perform a certain number of repetitions and sets of a required exercise, without any compensatory movements, he/she can proceed to the next level of exercise. Breaks between exercises and sets are the same as in the integral movement therapy protocol. Protocol consists of four basic exercises, which are progressed through sessions: (I) Abdomen curl. (II) Trunk extension on roman chair. (III) Hip bridge. (IV) Side plank.
Study NCT03623802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integral Movement Therapy
Description: Protocol consists of four basic exercises, which are progressed through sessions: (I) Proprioception - sitting on an unstable surface - Swiss ball, with additional tasks with legs and arms. (II) Strength - pushing task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (III) Strength - pulling task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (IV) Lifting and carrying the loads: a) Stoop lifting. b) Squat lifting. c) Half kneeling lifting.
Study NCT00598832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene lotion 0.1%
Description: Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
Study NCT00598832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adapalene Lotion Vehicle
Description: Adapalene Lotion Vehicle will be applied topically to the face, once a day, for 12 weeks
Study NCT01900704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120 750 ng
Description: SER120 750 ng
Study NCT01900704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120 1500 ng
Description: SER120 1500 ng
Study NCT01900704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01414010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Trametes versicolor extract
Description: 1,200 mg, 3 times daily on an empty stomach for 14 days
Study NCT01414010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces boulardii
Description: 250 mg, 3 times daily on an empty stomach for 14 days
Study NCT01414010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 250 mg 3 times daily at least 1 hour before meals for 7 days
Study NCT04134013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination: Nutrition AND Chiropractic Adjustment
Description: LBP chiropractic adjustment per protocol, nutrition counseling/ 4 Nutrient offerings (Vitamin Booster, Shake + 2 other offerings)
Study NCT03420508 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ALKATI by Customized Nanostring Assay
Description: a custom chip with probes targeting the ATI site in ALK, providing a reproducible, quantitative measure of ALKATI
Study NCT04134013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chiropractic Adjustment: Spinal Manipulation Therapy
Description: LBP chiropractic adjustment per protocol
Study NCT01700777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HABIT-ILE
Description: 90 h of training with HABIT-ILE, in an intensive rehabilitation camp compared with a regular therapy program (groups are crossed-over afterwards).
Study NCT01700777 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HABIT-ILE
Description: 90 h of training with HABIT-ILE, in an intensive rehabilitation camp compared with a regular therapy program (groups are crossed-over afterwards).
Study NCT02835404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle
Study NCT02835404 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic External Radiotherapy
Description: patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X rays (SSD)
Study NCT02835404 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic External Radiotherapy
Description: patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X rays (SSD)
Study NCT02835404 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 252-Cf Neutron Intracavitary Brachytherapy
Description: total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations
Study NCT02835404 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 252-Cf Neutron Intracavitary Brachytherapy
Description: total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations
Study NCT05509647 — intervention group
Intervention type: DRUG
Intervention: Unfractionated heparin
Description: Patients are treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa levels of 0.3-0.7 iE/ml
Study NCT03863379 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: whole body DXA
Description: Measurements of body composition may be used to study how lean body mass and body fat change during health and disease and have provided a research tool to study the metabolic effects of obesity and various wasting conditions. DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%.
Study NCT02947997 — intervention group
Intervention type: DEVICE
Intervention: OFDI capsule
Description: Imaging of esophagus using OFDI capsule and system
Study NCT02148198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NWT-03, an egg-white protein hydrolysate
Description: For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
Study NCT01231334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapsone plus Adapalene
Description: Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
Study NCT01231334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin/benzoyl peroxide plus Adapalene
Description: Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks
Study NCT01260688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally
Study NCT01260688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given orally
Study NCT02966288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toradol
Description: 3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.
Study NCT02966288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral NSAID
Description: 800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
Study NCT03938103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Go NAPSACC
Description: In the Enhanced delivery model, TA coaches will help centers create an implementation team and conduct a needs assessment to identify organizational strengths and challenges. TA coaches will also provide an orientation to Go NAPSACC and its online tools and help the team develop a plan to guide their Go NAPSACC efforts. The team will then work through 2 cycles of Go NAPSACC over 12 months. During each cycle (6 months), centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals. Throughout this 12-month period, TA coaches will provide monthly check-ins incorporating tailored support based on the results from the needs assessment. They will also organize 2-3 meetings among teams from different centers to reflect and share lessons learned.
Study NCT03938103 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Go NAPSACC
Description: In the Basic delivery model, TA coaches will provide an orientation to Go NAPSACC and its online tools to the center director. The director will then work 2 cycles of Go NAPSACC over 12 months. During each cycle (6 months), centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals. Throughout this 12-month period, TA coaches will provide monthly brief check-ins.
Study NCT00351767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Topically applied
Study NCT00351767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telbermin
Description: Topically applied
Study NCT03389412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin
Description: The children will be treated with 120 microgram/day the first two weeks. If the child is not completely dry, the dose will be increased to 240 microgram/day the rest of the study period (maximum eight weeks of treatment).